Skip to content
About
Supporter
Expert Index
Editorial Board
Editorial Team
Editorial Policy
Contact
Sign up
Visit
Home
(current)
Diseases
Parkinson's Disease
Multiple Sclerosis and Related Disorders
Headache
Amyotrophic Lateral Sclerosis
Epilepsy
Sleep Disorders
Stroke
Neuromuscular Disorders
Movement Disorders
View all Diseases
Topics
Biology
Diagnostics
Trial Updates
Treatment
Prevention
Surgery
Imaging
Genetics
COVID-19
View all Topics
Conferences
EHC 2022
AES 2022
WSC 2022
ECTRIMS 2022
EHDN 2022
MDS 2022
View all Conferences
Features
Podcasts
About
Supporter
Expert Index
Editorial Board
Editorial Team
Editorial Policy
Contact
Sign up
Neuromuscular Disorders
3:23
The significance of glial cells in the pathophysiology of ALS
Serge Przedborski
• 16 Sep 2022
8:29
Losmapimod as a potential treatment for facioscapulohumeral muscular dystrophy (FSHD)
Christopher Morabito
• 11 Apr 2022
2:44
Updates on peripheral autoimmune neurological conditions
Divyanshu Dubey
• 12 Apr 2022
3:13
Diagnostic work up of autoimmune neurological conditions
Divyanshu Dubey
• 12 Apr 2022
1:43
Immunotherapy strategies for autoimmune disorders of the nervous system
Divyanshu Dubey
• 12 Apr 2022
1:51
Phase II extension trial of CNM-Au8 in ALS
Matthew Kiernan
• 4 Apr 2022
1:49
The pipeline of late-stage therapeutic options for patients with ALS
Matthew Kiernan
• 4 Apr 2022
1:23
Future lines of research in synucleinopathies
Elizabeth Coon
• 1 Apr 2022
2:18
Using real-world data in SMA management
Anna Kostera-Pruszczyk
• 25 Jun 2022
0:48
The diagnostic evaluation of hereditary and acquired neuromuscular diseases
Anna Kostera-Pruszczyk
• 27 Jun 2022
1:46
AOCs: future outlooks in other disease areas
Arthur Levin
• 6 Apr 2022
4:11
AOCs in neuromuscular disorders: Duchenne muscular dystrophy
Arthur Levin
• 6 Apr 2022
3:24
Optimization of myasthenia gravis management: knowledge gaps
James F. Howard Jr.
• 12 Apr 2022
1:53
AOC for the treatment of Duchenne muscular dystrophy in exon 44 skippers
Arthur Levin
• 6 Apr 2022
4:27
AOC programs in development for DMD and myotonic dystrophy
Arthur Levin
• 6 Apr 2022
2:52
Complement inhibitor therapy for myasthenia gravis: current and future outlooks
James F. Howard Jr.
• 12 Apr 2022
1
2
3
4
5
Next